121. Ziegelstein RC, Fauerbach JA, Stevens SS, Romanelli J, Richter DP, Bush DE. Patients with depression are less likely to follow recommenddations to reduce cardiac risk during recovery from a myocardial infarction. Arch Intern Med 2000;160:1818–23.
122. Anonymous. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980;303:1038–41.
123. Horwitz RI, Viscoli CM, Berkman L, Donaldson RM, Horwitz SM, Murray CJ, Ransohoff DF, Sindelar J. Treatment adherence and risk of death after a myocardial infarction. Lancet 1990;336:542–5.
124. McDermott MM, Schmitt B, Wallner E. Impact of medication nonadherence on coronary heart disease outcomes. A critical review. Arch Intern Med 1997;157:1921–9.
125. Danker R, Goldbourt U, Boyko V, Reicher-Reiss H. Predictors of cardiac and noncardiac mortality among 14,697 patients with coronary heart disease. Am J Cardiol 2003;91:121–7.
126. Fuchs CS, Stampfer MJ, Colditz GA, Giovannucci EL, Manson JE, Kawachi I, Hunter DJ, Hankinson SE, Hennekens CH, Rosner B. Alcohol consumption and mortality among women. NEJM 1995;332:1245–50.
127. Rehm JT, Bondy SJ, Sempos CT, Vuong CV. Alcohol consumption and coronary heart disease morbidity and mortality. Am J Epidem 1997;146:495–501.
128. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001;104:1894–8.
129. Roose SP, Glassman AH, Attia E, Woodring S. Giardina EGV, Bigger J Jr. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998;155:5:660–5.
130. Strik JJ, Honig A, Lousberg R, Lousberg AH, Cheriex EC, Tuynman-Qua HG, Kuijpers PM, Wellens HJ, Van Praag HM. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med 2000;62:783–9.
131. Pohl R, Balon R, Jayaraman A, Doll RG, Yeragani V. Effect of fluoxetine, pemoline and placebo on heart period and QT variability in normal humans. J Psychosom Res 2003;55:247–51.
132. Shapiro PA, Lesperance F, Frasure-Smith N, O’Connor CM, Baker B, Jiang JW, Dorian P, Harrison W, Glassman AH. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Am Heart J 1999;137: 1100–6.
133. Glassman AH, O’Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, Krishnan KR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM, Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288:701–9.
134. Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EGV. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991;148:512–6. Taylor CB, Houston-Miller N, Ahn DK, Haskell W, DeBusk RF.
135. The effects of exercise training programs on psychosocial improvement in uncomplicated postmyocardial infarction patients. J Psychosom Res 1986;30:581–7.
136. Duncan JJ, Farr JE, Upton SJ, Hagan RD, Oglesby ME, Blair SN. The effects of aerobic exercise on plasma catecholamines and blood pressure in patients with mild essential hypertension. JAMA 1985;254:2609–13.
137. Claytor RP. Stress reactivity: hemodynamic adjustments in trained and untrained humans. Med Sci Sports Exerc 1991;23:873–81.
138. Cox RH. Exercise training and response to stress: insights from an animal model. Med Sci Sports Exerc 1991;23:853–9.
139. Dienstbier RA. Behavioral correlates of sympathoadrenal reactivity: the toughness model. Med Sci Sports Exerc 1991;23:846–52.
140. Blumenthal JA, Fredrikson M, Matthews KA, et al. Stress reactivity and exercise training in premenopausal and postmenopausal women. Health Psychol 1991;10:384–91.
141. Wittert GA, Livesey JH, Espiner EA, Donald RA. Adaptation of the hypothalamopituitary adrenal axis to chronic exercise stress in humans. Med Sci Sports Exerc 1996;28:1015–9.
142. Luger A, Deuster PA, Kyle SB, Gallucci WT, Montgomery LC, Gold PW, Loriaux DL, Chrousos GP. Acute hypothalamic-pituitary-adrenal responses to the stress of treadmill exercise. Physiologic adaptations to physical training. N Engl J Med 1987;316:1309–15.
143. Mikines KJ, Sonne B, Tronier B, Galbo H. Effects of training and detraining on dose-response relationship between glucose and insulin secretion. Am J Physiol 1989;256:E588–96.
144. Ford ES. Does exercise reduce inflammation? Physical activity and C-reactive protein among US adults. Epidemiology 2002;13:561–8.
145. Kop WJ, Appels AP, Mendes de Leon CF, de Swart HB, Bar FW. Vital exhaustion predicts new cardiac events after successful coronary angioplasty. Psychosom Med 1994;56:281–7.
146. Denollet J, Brutsaert DL. Personality, disease severity, and the risk of long-term cardiac events in patients with a decreased ejection fraction after myocardial infarction. Circulation 1998;97:167–73.
147. Kawachi I, Sparrow D, Kubzansky LD, Spiro A, III, Vokonas PS, Weiss ST. Prospective study of a self-report type A scale and risk of coronary heart disease: test of the MMPI-2 type A scale. Circulation 1998;98: 405–12.
148. Angerer P, Siebert U, Kothny W, Muhlbauer D, Mudra H, von Schacky C. Impact of social support, cynical hostility and anger expression on progression of coronary atherosclerosis. J Am Coll Cardiol 2000;36:1781–8.
149. Chaput LA, Adams SH, Simon JA, Blumenthal RS, Vittinghoff E, Lin F, Loh E, Matthews KA. Hostility predicts recurrent events among postmenopausal women with coronary heart disease. Am J Epidemiol 2002;156:1092–9.
150. Kubzansky LD, Kawachi I. Going to the heart of the matter: do negative emotions cause coronary heart disease?. J Psychosom Res 2000;48: 323–37.
151. Frasure-Smith N, Lesperance F. Depression and other psychological risks following myocaridal infarction. Arch Gen Psychiatry 2003;60: 627–36.
152. Unutzer J, Patrick DL, Simon G, et al. Depressive symptoms and the cost of health services in HMO patients aged 65 years and older: a 4-year prospective study. JAMA. 1997;28:277:1618–1623.
153. Judd LL. Surveys show that 20–30% of elderly patients exhibit SSD symptomatology. Int Med World Rep. 1997;12:33–34.
154. Ford DF, Mead LA, Chang PP, et al. Depression predicts cardiovascular disease in men: the Precursors Study. Arch Intern Med. 1998:158: 1422–1426.
155. Pratt LA, Ford DE, Crum RM, et al. Depression, psychotropic medication, and risk of myocardial infarction: prospective data from the Baltimore ECA follow-up. Circulation. 1996;94:3123–3129.
156. Anda R, Williamson D, Jones D, et al. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of US adults. Epidemiology. 1993;4:285–294.
157. Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation. 1996; 93:1976–1980.
158. Everson SA, Goldberg DE, Kaplan GA, et al. Hopelessness and risk of mortality and incidence of myocardial infarction and cancer. Psychosom Med. 1996;58:113–121.
159. Wassertheil-Smoller S, Applegate WB, Berge K, et al, for the SHEP Cooperative Research Group. Change in depression as a precursor of cardiovascular events. Arch Intern Med. 1996;156:553–561.
160. Penninx BW, Guralnik JM, Mendes de Leon CF, et al. Cardiovascular events and mortality in newly and chronically depressed persons .70 years of age. Am J Cardiol. 1998;81:988–994.